Search results
AbbVie (ABBV) Skyrizi Gets CHMP Nod for Ulcerative Colitis in EU
Zacks via Yahoo Finance· 1 week agoAbbVie (ABBV) announces that the EMA's CHMP issued a positive opinion on its regulatory filing...
AbbVie's (ABBV) Skyrizi Gets FDA Nod for Crohn's Disease
Zacks via Yahoo Finance· 2 years agoThe FDA approval of AbbVie's (ABBV) Skyrizi for moderately to severely active Crohn's disease was...
Pharma Stock Roundup: MRK to Buy IMGO, ABBV's Skyrizi Gets EU Nod for New Indication
Zacks via Yahoo Finance· 2 years agoThis week, Merck MRK offered to buy Imago Biosciences IMGO, which is developing drugs to treat bone...
Pharma Stock Roundup: FDA OK's Expanded Use of ABBV, MRK, NVS Drugs, Other Updates
Zacks via Yahoo Finance· 2 years agoThe FDA approves expanded use of AbbVie's (ABBV) Skyrizi, Merck's (MRK) Vaxneuvance vaccine and...
Can AbbVie's (ABBV) New Drugs Make up for Lost Humira Sales?
Zacks via Yahoo Finance· 2 years agoAbbVie's (ABBV) new drugs, Skyrizi and Rinvoq, are faring well, bolstered by approval in new...
Can AbbVie (ABBV) Protect Revenues After Humira Patent Loss?
Zacks via Yahoo Finance· 10 months agoAbbVie’s ABBV key blockbuster immunology medicine, Humira lost patent protection in the United...
AbbVie (ABBV) Q2 2022 Earnings Call Transcript
Motley Fool· 2 years agoImage source: The Motley Fool. AbbVie (NYSE: ABBV) Q2 2022 Earnings Call Jul 29, 2022, 9:00 a.m. ET Contents: Prepared Remarks Questions and Answers Call...
Here's What's Driving AbbVie's (ABBV) Outperformance This Year
Zacks via Yahoo Finance· 2 years agoAbbVie (ABBV) boasts several new drugs with the potential to drive revenues once Humira loses U.S....
Pharma Stock Roundup: LLY's CFO Departs, ABBV, AZN Drugs Get CHMP Approval
Zacks via Yahoo Finance· 3 days agoThis week, Eli Lilly LLY announced that Anat Ashkenazi, who served the company for 23 years, has...
State board targets six prescription drugs to review for affordability for Marylanders
Maryland Matters via Yahoo News· 3 weeks agoThe board will seek public comments, additional information and data over the next 60 days to...